Annexon appoints Dr. Bettina Cockroft to board of directors

Annexon, Inc.

Dr. Cockroft is SVP and CMO of Sangamo Therapeutics, effective immediately.
Appointed as Class III director with term expiring at 2023 annual meeting.
Receives $35,000 annual retainer, initial option for 20,000 shares, and annual grant for 10,000 shares.
She brings nearly 20 years of clinical development experience in neurodegenerative and movement disorders.
Annexon highlights her expertise as it advances complement-mediated therapies in GBS and Huntington's disease.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bettina M. Cockroft

Director

ANNX · Annexon, Inc.

Effective: 2022-01-19
Filed: January 20, 2022, 6:59 PM ET

On January 19, 2022, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., to the Board, effectively immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bettina M. Cockroft was appointed as Director at Annexon, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 19, 2022, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed Bettina M. Cockroft, M.D., to the Board, effectively immediately.

View on SEC.gov

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-013774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.